Global Treatment Resistant Depression Market Overview:
TRD is a relatively common occurrence in clinical practice.Treatment-resistant depression, a complex clinical problem caused by multiple risk factors, is targeted by integrated therapeutic strategies, which include optimization of medication and augmentation with non-antidepressants, psychosocial and cultural therapies. The complexity of treatment for TRD reflects the diverse nature of the disorder, and the provider should be careful to make an accurate diagnosis before treatment. Treatment-resistant depression is a difficult condition to treat. Patients with the disorder should interactively share their inner experiences with the treating expert and be able to ask freely any questions related to risk factors underlying treatment-resistant depression, duration of treatment, severity of side effect, suicidal thoughts and attempts, non-suicidal self-injurious behaviors, and intolerance issues.
- Rising prevalence of the depressive disorder
- Lack of awareness about depression among people
- High governmental healthcare expenditure
- Lack of trained professionals
- High-cost of treatment
The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies.
Some of the key players profiled in the report are Bristol Myers Squibb Company (United States), Janssen Pharmaceuticals, Inc. (Belgium), Otsuka Pharmaceutical Co., Ltd. (Japan), Mylan Pharmaceuticals, Inc. (United States), Pfizer, Inc (United State), Novartis AG (Switzerland), Eli Lilly and Company (United States), Wyeth (United States) and Validus Pharmaceuticals LLC (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Treatment Resistant Depression market by 2026. Considering Market by Signs of Depression , the sub-segment i.e. Less interest in activities will boost the Treatment Resistant Depression market. Considering Market by Medication , the sub-segment i.e. Selective serotonin reuptake inhibitors (SSRIs) will boost the Treatment Resistant Depression market. Considering Market by Forms of Treatment, the sub-segment i.e. Cognitive-behavioral therapy will boost the Treatment Resistant Depression market.
On 3 August 2020 The Janssen Pharmaceutical Companies of Johnson & Johnson announced that the U.S. Food and Drug Administration (FDA) has approved the supplemental new drug application for SPRAVATO CIII nasal spray, taken with an oral antidepressant, to treat depressive symptoms in adults with major depressive disorder (MDD) with acute suicidal ideation or behavior.1 SPRAVATO is the first and only approved medicine that has been shown to reduce depressive symptoms within 24 hours,1 providing a new option for significant symptom relief until a longer-term, comprehensive treatment plan can take effect.
What Can be Explored with the Treatment Resistant Depression Market Study
Gain Market Understanding
Identify Growth Opportunities
Analyze and Measure the Global Treatment Resistant Depression Market by Identifying Investment across various Industry Verticals
Understand the Trends that will drive Future Changes in Treatment Resistant Depression
Understand the Competitive Scenario
- Track Right Markets
- Identify the Right Verticals
The top-down and bottom-up approaches are used to estimate and validate the size of the Global Treatment Resistant Depression market.
In order to reach an exhaustive list of functional and relevant players various industry classification standards are closely followed such as NAICS, ICB, SIC to penetrate deep in important geographies by players and a thorough validation test is conducted to reach most relevant players for survey in Treatment Resistant Depression market.
In order to make priority list sorting is done based on revenue generated based on latest reporting with the help of paid databases such as Factiva, Bloomberg etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment by targeting key target audience that includes Treatment-Resistant Depression Provider, New Entrants and Investors, Venture Capitalists, Government Bodies, Corporate Entities, Government and Private Research Organizations and Others.
This helps us to gather the data related to players revenue, operating cycle and expense, profit along with product or service growth etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that includes Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, USPTO, EPO, Annual reports, press releases etc.